Background Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been
associated with relapse prevention through the clearance of P. vivax parasitemia and …

As international travel becomes increasingly common and resistance to antimalarial drugs
escalates, a growing number of travelers are at risk for contracting malaria. Parasite …

Malaria constitutes one of the major health threats in the tropical and sub-tropical areas of
the world. Yet, few advances were made in recent years in revealing the mode of action of …

The number of available and effective antimalarial drugs is quickly dwindling. This is mainly
because a number of drug resistance-associated mutations in malaria parasite genes, such …

Tafenoquine is a newly licensed antimalarial drug for the radical cure of Plasmodium vivax
malaria. The mechanism of action and optimal dosing are uncertain. We pooled individual …

Relapses of Plasmodium vivax malaria are prevented by 8-aminoquinolines. If hypnozoites
survive, then the subsequent blood stage infections in early relapses (< 2 months) are …

Millions of people receive primaquine against sexual plasmodia responsible for malaria
transmission. These gametocytes cause no symptoms and do not threaten the host, but they …

Primaquine phosphate has been used for preventing relapse of Plasmodium vivax and P.
ovale malaria since the early 1950s, based on its ability to kill latent (hypnozoite) and …

According to WHO, 2019 witnessed 229 million cases of malaria globally, of which Africa
accounted for 94% of cases. Early diagnosis and treatment are the basis of malaria …

Background The 8‐aminoquinoline (8AQ) drugs act on Plasmodium falciparum
gametocytes, which transmit malaria from infected people to mosquitoes. In 2012, the World …